Nicky has extensive experience in the evaluation of new technologies and the founding, coaching and support of startups in the life sciences. She has started her career as a business developer within a Dutch technology transfer office and then made the switch to business, where she has been active in different Business Development roles in start up companies.
For Swanbridge Capital, she is responsible for the evaluation of the investment proposals, the deal making and the coaching of the start-up companies.
In addition to her activities for Swanbridge Capital, Nicky is the Executive Vice President, Global Business Development at SkylineDx.
Dharminder has built an extensive network in the life science industry and holds a strong track record in direct involvement of complex corporate transactions. These include the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Octoplus to Dr. Reddy’s.
At Swanbridge Capital, Dharminder has an important role in the valuation of our portfolio companies, as well as ensuring follow-up investment.
Besides his activities at Swanbridge Capital Dharminder is CEO and founder of SkylineDx, owner and managing director of Exponential BV, as board member or advisor he is active for several companies and Venture Capital funds in the field of life sciences.
Cillian joined the team in 2018 following a career in strategic consultancy for early-stage ventures in the Life Sciences industry. As a consultant, Cillian gained extensive experience in the valuation of novel healthcare technologies, business development, project management, and non-dilutive funding.
In addition to working with early-stage ventures, Cillian was also involved in setting up several Dutch investment funds, including Swanbridge Capital in 2016. Cillian has a background in Molecular Biology (VU University and MIT) and a PhD in Molecular Neuroscience (VU University).
At Swanbridge Capital, Cillian is responsible for sourcing and evaluating investment proposals, deal making, and the management of portfolio companies.
Hans Schikan brings more than 25 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases. During Mr. Schikan’s leadership, Prosensa was listed on NASDAQ in a successful IPO in June 2013, and acquired by BioMarin early 2015 for USD 680 million.
Previous assignments include Vice President, Marketing and Strategic Development for the rare disease portfolio of Genzyme and several senior commercial roles in Organon.
He is currently on the board of a number of biotechnology companies in The Netherlands, Belgium, Sweden and Switzerland. He is also member of the core team of the Dutch Top Sector for Life Sciences and Health.
With over 15 years of experience as CFO of the Van Herk Group, Erik Esveld brings a wealth of experience in Life Science investments. The Van Herk Group is one of the major private Life Science investors in the Benelux, with positions in Galapagos, Nightbalance among others and various Life Science funds.
For the last three years Erik is part of the nominating committee at BioInvent. Since early 2016 he holds a position in the supervisory board of the Amsterdam based molecular diagnostic company Agendia.
Gerty has worked more than 20 years in the field of assisting high tech start-ups, as an investment-manager of various seed funds and as consultant. In 1991 she started her career at the Zernike Science Park, as investment manager for the Zernike Seed Fund. She worked for a couple of years as a staff member for the Dutch Advisory Council for Science and Technology, and as manager of the Amsterdam Science Park.
She has been involved in the creation of over 100 companies, from 2000 on focusing on the life sciences sector as investment manager of the BioPartner Start-up Ventures Fund. In 2014 she joined InnovationQuarter as a senior investment-manager Life Sciences.
David Voetelink has over 15 years of experience in the finances of Health Care organizations. Working as a chartered accountant and partner at KPMG David has been chair of KPMG Health Care for 13 years.
In 2013 he joined the board of directors at the Erasmus University Medical Center as CFO. The Erasmus MC ranks amongst the top European medical research institutions. Mr. Voetelink’s expertise is in financial control of healthcare organizations and financial change and administration.
Brainpark II - Building XI
3062 ME Rotterdam
© 2016 Swanbridge Capital